Daron Evans buys 51,500 shares.CEO Daron Evans purchased 51,500 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $0.53 per share, for a total transaction of $27,295.00. Following the completion of the purchase, the chief executive officer now owns 125,584 shares in the company, valued at approximately $66,559.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission,
Old news...from the last 10k:
Anti-arenavirus Drug Development
In August 2011, we received a 5-year grant of $7.7 million from NIH to continue funding for the development of antiviral drugs for Lassa fever virus. In connection with the Optimization Program, in August 2014, the Company entered into an asset purchase agreement to sell and transfer its pre-clinical Anti-arenavirus assets and research and development to Kineta Four, LLC, an unrelated party (see Note 3 to the financial statements).
MannKind Corp. (NASDAQ: MNKD) is still one of the biggest battleground stocks out there in the realm of biotech and emerging pharma. After getting U.S. Food and Drug Administration (FDA) approval for the inhalable insulin Afrezza, the real push and launch has gotten off to a slow start with very slow use adoption. Then shares of MannKind tanked, only to almost double from their 52-week low in a period of just the past month.
24/7 Wall St. has seen both sides of the coin on MannKind, and the most obvious issue here is that it is not just going to be a battleground stock ahead. It likely will be a tug-of-war stock, each day and each week ahead, until a more clear direction and long-term path is known.
The first tug-of-war is of course going to be how the public reacts to the inhalable insulin named Afrezza. Most doctors do not know enough about Afrezza to prescribe it. Of the doctors that do know Afrezza is approved, many remain more concerned than optimistic. The same appears to be true for many patients. That will be a serious tug-of-war.
Jefferies has remained very positive in its research report on MannKind. Goldman Sachs was very negative, but MannKind is set to present at the Goldman Sachs health care conference this week. You could have Jefferies covering this one endlessly with bullish views, and you could have Goldman Sachs covering it negatively. Then there are other analysts as well.
ALSO READ: 9 Analyst Stocks Under $10 With Huge Upside
Reports have included issues such as a coming capital raise from MannKind. While a capital raise helps the company’s cash and long-term viability, it either adds on debt or it ultimately dilutes shareholders. That means that long-term holders will fight traders in the near term over which direction the stock will go. Tug-of-war!
The short interest from the end of May is not yet out, but will be in hours. We just showed how the short sellers were likely being shaken out, but the reality is that short sellers often stay short or stay negatively biased for more than just weeks. That means the short sellers likely will remain active.
Momentum traders are likely to remain active here. That also means big buying, followed by big selling — and not just in that order. Tug-of-war!
Options traders may create another tug-of-war. The June 12, 2015, weekly expiration options had over 10,000 call contracts and over 5,000 put contracts in the open interest. Each 10,000 contracts, with each contract consisting of the right to buy or sell 100 shares, accounts for a million shares on a fully leveraged basis. The June 19 puts and calls are even more active — far more active, due to those being the monthly expiration that would have been bought weeks and months ahead.
ALSO READ: Are Airlines Stocks Oversold as Analysts Abandon Them?
Anyhow, there are of course more issues to consider with Afrezza and MannKind. Either way, the tug-of-war status looks as though it will remain in place for some time.
MannKind shares were down 5.3% to $6.85 Tuesday afternoon. The stock has a consensus analyst price target of $7.46 and a 52-week trading range of $3.46 to $11.48. The company has a market cap of $2.8 billion.
By Jon C. Ogg
The conference call will include a presentation followed by a Q&A session. It will be accessible through audio webcast and via the following telephone numbers:
Call in numbers
France: +33 (0) 1 70 77 09 40
UK: +44 (0) 203 367 94 53
USA: +1 866 907 59 28
Audio replay (available approximately 2 hours after the end of the call)
France: +33 (0) 1 72 00 15 00
UK: +44 (0) 203 367 94 60
USA: +1 877 642 30 18
Access code: 293697#